Interim Marketing Of New OTC Conditions Prohibited Under Proposed Rule

Final monograph status would be required before a new OTC condition could be sold in the U.S. under FDA's proposed rule on "material time, material extent" published in the Federal Register Dec. 20. Interim marketing of conditions deemed eligible for monograph consideration would not be allowed.